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Abstract: The loss of effectiveness of current antibiotics caused by the development of drug resis-
tance has become a severe threat to public health. Current widely used antibiotics are surprisingly tar-
geted at a few bacterial functions - cell wall, DNA, RNA, and protein biosynthesis - and resistance to 
them is widespread and well identified. There is therefore great interest in the discovery of novel drugs 
and therapies to tackle antimicrobial resistance, in particular drugs that target other essential processes 
for bacterial survival. In the past few years a great deal of effort has been focused on the discovery of 
new inhibitors of the enzymes involved in the biosynthesis of aromatic amino acids, also known as the 
shikimic acid pathway, in which chorismic acid is synthesized. The latter compound is the synthetic precursor of L-Phe, 
L-Tyr, L-Phe, and other important aromatic metabolites. These enzymes are recognized as attractive targets for the devel-
opment of new antibacterial agents because they are essential in important pathogenic bacteria, such as Mycobacterium 
tuberculosis and Helicobacter pylori, but do not have any counterpart in human cells. This review is focused on two key 
enzymes of this pathway, shikimate kinase and type II dehydroquinase. An overview of the use of structure-based design 
and computational studies for the discovery of selective inhibitors of these enzymes will be provided. A detailed view of 
the structural changes caused by these inhibitors in the catalytic arrangement of these enzymes, which are responsible for 
the inhibition of their activity, is described. 
Keywords: Dehydroquinase, Enzyme/inhibitor crystal structures, Essential enzyme motion, Intermediate mimetics, Molecular 
dynamics simulation studies, Shikimate kinase, Structure-based design, Substrate analogs. 
1. INTRODUCTION 
The increasing development and spread of resistance to 
current antibiotics have turned ordinary bacterial infections 
into illnesses that cannot be controlled. Infections from 
resistant bacteria are now too common and some pathogens 
have even become resistant to multiple types of antibiotics. 
The lack of effective antibiotics will undermine our ability 
to fight infectious diseases and manage the infectious com-
plications common in vulnerable patients undergoing che-
motherapy for cancer, dialysis for renal failure, and sur-
gery, especially organ transplantation, for which the ability 
to treat secondary infections is crucial. In addition, antibac-
terial drug resistance also has a huge economic impact on 
individuals as well as healthcare systems and societies 
[1,2]. The European Centre for Disease Prevention and 
Control (ECDC) estimates that antimicrobial resistance 
results each year in 25,000 deaths and related costs of over 
€1.5 billion in healthcare expenses and productivity losses. 
However, despite this alarming trend, research into the dis-
covery of new antibiotics by large pharmaceutical compa-
nies has dwindled dramatically [3,4]. Therefore, there is  
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great interest in the discovery of novel drugs and therapies to 
treat antibiotic-resistant infections and, in particular, of drugs 
with new mechanisms of action. The most widely used strat-
egy to combat bacterial infections is based on the disruption 
of the growth cycle by preventing the synthesis and assem-
bly of key components of bacterial processes [5,6]. Many 
drugs that are highly successful in human clinical use mimic 
a substrate, a transition state or a product of essential en-
zymes. A detailed knowledge of the catalytic mechanism and 
the binding determinants of those enzymes can be valuable 
for the rational design of these mimetics (inhibitors) that can 
be used as drugs. The increasing availability in recent years 
of crystal structures of enzyme/inhibitor complexes has un-
doubtedly been very important to gain a deeper understand-
ing of the enzymatic mechanisms and for the development of 
potent inhibitors of the selected targets. This success has also 
benefitted extensively from the recent advances in computa-
tional methods that have consolidated their value as impor-
tant complementary tools that can assist in the elucidation of 
how these reactions are catalyzed, the binding requirements 
and the essential motions required for catalysis.  
On the other hand, the increasing availability of bacterial 
genome sequences has created new opportunities for drug 
discovery. The identification of essential genes and the pro-
teins encoded by them provides an excellent starting point 
for uncovering novel and important biological processes in  
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microorganisms [7]. In fact, current widely used antibiotics 
are surprisingly targeted at a very small number of key bac-
terial functions, such as cell wall, DNA, RNA, and protein 
biosynthesis, and resistance to these antibiotics is widespread 
and well known [8]. Targeting of new pathways will likely 
play an important role in the discovery of new antibiotics to 
combat the growing problem of antibiotic-resistant bacteria. 
For this purpose, much attention has been devoted to the 
inhibition of the enzymes involved in the shikimic acid 
pathway in recent years. This is a biosynthetic route through 
which erythrose-4-phosphate (1) and phosphoenol pyruvate 
(2) are converted to chorismic acid (9), the precursor in the 
synthesis of aromatic amino acids, L-Phe, L-Tyr and L-Thr, 
and folate cofactors, ubiquinone and vitamins E and K 
(Scheme 1) [9]. The absence of this pathway in mammals, 
combined with its essential nature in certain micro-
organisms, makes it an attractive target for the development 
of new antimicrobial agents [10]. The important features of 
the shikimic acid pathway have not gone unnoticed by the 
scientific community and in the past few years a great deal 
of effort has been focused on the discovery of new inhibitors 
of the enzymes involved in this route. In this review, we 
summarize examples of the use of structure-based design and 
computational studies in the development of selective inhibi-
tors of two key enzymes of the shikimic acid pathway that 
are essential for bacterial survival. The review is focused on 
the structural changes (binding, motion, conformation) 
caused by these compounds, which are responsible for their 
inhibitory activity. This information helps to rationalize the 
determinants of binding affinity for inhibitors and could pro-
vide guidelines for future inhibitor design. 
2. THE SHIKIMIC ACID PATHWAY ENZYMES – 
ATRACTIVE TARGETS FOR DRUG DISCOVERY 
The enzymes involved in the shikimic acid pathway are 
present in bacteria, fungi and higher plants, but they are ab-
sent in mammals. Some of these enzymes have also been 
detected in Toxoplasma gondii (which causes malaria) and 
Plasmodium falciparum extracts, indicating that a complete 
shikimic acid pathway is present in this parasite [11,12]. 
However, only a single gene encoding the last enzyme of the 
pathway, chorismate synthase, has been identified conclu-
sively in the genome annotation. It has been suggested that 
these missing enzymes are either substituted by non-
homologous enzymes that catalyze the same reactions, or 
that the enzymes are homologous but are too divergent to be 
identified readily [13]. A good example of the utility of this 
Scheme 1. The shikimic acid pathway. The reaction catalyzed by the dehydroquinase enzyme is also part of the quinic acid pathway that 
converts quinic acid (10) into protocatechuate (11). The genes encoding the enzymes involved in both pathways are also indicated in brack-
ets. 
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target is glyphosate [N-(phosphonomethyl)glycine], the ac-
tive ingredient in the well-known herbicides RoundUp®, 
Zero® and Tumbleweed®. Glyphosate is a specific inhibitor 
of the sixth enzyme of the shikimate pathway [5-
enolpyruvylshikimate-3-phosphate (EPSP) synthase] with a 
Ki of 1 µM [14] and it has proven to be active in vitro against 
malaria [11]. Structural studies have shown that glyphosate 
occupies the phosphoenol pyruvate binding site in the en-
zyme, mimicking an intermediate state of the ternary enzyme 
substrate complex [15,16]. The shikimic acid pathway starts 
with the condensation of erythrose-4-phosphate (1) and 
phosphoenol pyruvate (2) catalyzed by DAHP synthase (7-
phosphono-2-dehydro-3-deoxyheptonate aldolase, EC 
4.1.2.15) to give DAHP (3, 3-deoxy-D-arabino-
heptulosonate-7-phosphate), which is converted into 3-
dehydroquinic acid (4) by dehydroquinate synthase (EC 
4.6.1.3) (Scheme 1). This transformation involves an oxida-
tion and a reduction reaction, a phosphate cleavage and an 
intramolecular aldol condensation using NAD+ as cofactor. 
The next step is the reversible dehydration of 3-
dehydroquinic acid (4) into 3-dehydroshikimic acid (5) cata-
lyzed by dehydroquinase (EC 4.2.1.10). This transformation 
is common to the shikimic acid biosynthetic pathway leading 
to chorismic acid (9) and to the quinic acid catabolic path-
way that converts quinic acid (10) into protocatechuate (11) 
via 3-dehydroquinic acid (4) and 3-dehydroshikimic acid (5) 
in reactions catalyzed by quinate dehydrogenase (EC 
1.1.1.24), dehydroquinase and 3-dehydroshikimate dehydra-
tase (EC 4.2.1.118). The fourth step of the shikimic acid 
pathway is the reversible reduction of 3-dehydroshikimic 
acid (5) to shikimic acid (6) using NADPH as cofactor and it 
is catalyzed by shikimate dehydrogenase (EC 1.1.1.25). The 
selective phosphorylation of the C3 hydroxyl group of 
shikimic acid (6) by ATP catalyzed by shikimate kinase (EC 
2.7.1.71) then takes place to give shikimate 3-phosphate (7). 
The enolpyruvyl group of phosphoenol pyruvate (2) is then 
transferred onto shikimate 3-phosphate (7) to give EPSP (8) 
and phosphate in a process that is catalyzed by EPSP syn-
thase (EC 2.5.1.19). The last step of the pathway is the 
elimination of the phosphate group in EPSP (8) catalyzed by 
chorismate synthase (EC 4.2.3.5) to form chorismic acid (9). 
With the exception of the qa-3 gene that encodes for 
quinate dehydrogenase, all of the gene-encoding enzymes 
involved in the quinic and shikimic acid pathways have been 
sequenced. DAHP synthase has three isoenzymes, one for 
each aromatic amino acid, and three different genes, aroF, 
aroG, and aroH, specifically encode each one of these en-
zymes, which allows control of the production of each amino 
acid, Tyr, Phe and Thr, respectively. The enzymes involved 
in the shikimic acid pathway are particularly attractive tar-
gets for the development of new anti-tubercular therapies 
because six of the seven enzymes, specifically, the ones en-
coded by aroF, aroG, aroB, aroD, aroE, aroK and aroA 
genes, are essential for Mycobacterium tuberculosis, which 
is the causative agent of tuberculosis [17]. Hence, it is not 
surprising that many developed inhibitors have focused on 
the disruption of the growth cycle of this bacterium, which 
will be discussed below. Also remarkable is the potential of 
these enzymes for the treatment of Helicobacter pylori infec-
tions. This bacterium is the causative agent of gastric and 
duodenal ulcers and has also been classified as a type I car-
cinogen. For this bacterium four enzymes of this route are 
essential, specifically dehydroquinase, shikimate dehydro-
genase, shikimate kinase and chorismate synthase (aroQ, 
aroE, aroK and aroC genes). This review will provide an 
overview of the most important inhibitors that have been 
developed against two key enzymes for M. tuberculosis and 
H. pylori survival, specifically shikimate kinase (aroK) and 
type II dehydroquinase (aroD/aroQ), which are the fifth and 
the third enzymes of the shikimic acid pathway.  
3. TARGETING SHIKIMATE KINASE 
Shikimate kinase (SK) catalyzes the stereospecific phos-
phorylation of the C3 hydroxyl group of shikimic acid (6) by 
transferring the γ-phosphate group of ATP to the hydroxyl 
group to provide shikimate 3-phosphate (7) and ADP. In 
Escherichia coli there are two types of enzymes, SK I, en-
coded by the aroK gene, and SK II, encoded by the aroL 
gene. However, most bacteria only have one type of SK. 
The SK enzyme is essential in Mycobacterium tuberculo-
sis, Helicobacter pylori, Acinetobacter baylyi, Haemophilus 
influenzae, Francisella novicida and Pseudomonas aerugi-
nosa. In addition, it has also been shown that the antimicro-
bial properties of glyphosate are not only due to EPSP inhi-
bition, as mentioned previously, but also to the high concen-
trations of shikimic acid and protocatechuate that it causes 
[18,19]. These important features have encouraged diverse 
research groups to study in detail the substrate binding re-
quirements of this enzyme [20-25]. As a result, several crys-
tal structures of SK, mainly from M. tuberculosis, have been 
reported, either as binary complexes with ATP, ADP or 
shikimic acid (6) in the active site, or as tertiary complexes 
with ADP/shikimic acid (6) or ADP/shikimate 3-phosphate 
(7) [20-23]. These structures have been an excellent starting 
point for the structure-based design of inhibitors, which will 
be discussed below. 
3.1. Substrate Recognition 
SK is a magnesium-dependent enzyme that has two rec-
ognition centers, one for shikimic acid (6) and another for 
the cofactor (ATP), with different key interactions in both 
cases. SK has three domains (Fig. 1A) [20]: (1) the CORE 
domain containing five-stranded parallel β-sheets and the 
P-loop [residues 9-17 in SK from M. tuberculosis (Mt-
SK)], which forms the binding site for ATP and ADP; (2) 
the LID domain (residues 112-124 in Mt-SK), which closes 
over the active site and has residues that are essential for 
the binding of ATP; and (3) the substrate binding (SB) do-
main (residues 33-61 in Mt-SK), which is responsible for 
the recognition and binding of shikimic acid (6). The SB 
domain is highly conserved and involves a number of 
charged residues, specifically Arg136, Arg58, Glu61, 
Asp34, Arg117 and Lys15, and a lipophilic pocket formed 
by Phe49, Phe57, Pro118, Gly79, Gly80 and Gly81 (in Mt-
SK). Circular dichroism [21], fluorescence [22] and struc-
tural [20-24] studies suggested that ATP first binds to the 
enzyme and induces a large movement of the LID domain 
over the active site. Shikimic acid (6) subsequently binds to 
the active site and the LID domain closes over the active 
site and brings Arg110 and Arg117 into the ATP and SB 
domains, respectively [20].  
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Fig. (1). A) Michaelis complex of Mt-SK obtained by MD simulation studies [25]. The three domains of SK are shown: CORE (green), LID 
(blue) and SB (magenta). B) Detail view of the relevant binding interactions of shikimic acid (6) and ATP in the Mt-SK active site. Relevant 
side chain residues are shown and labeled. Hydrogen bonding interactions between the substrates and the enzyme are shown as dashed red 
lines. C) Representative snapshots of the shikimate-3-phosphate (7) release from the active site of Mt-SK obtained by MD simulations (10 
ns). Note the large conformational changes of the LID and the α-helices α3 and α2 of the SB binding domains during product release. 
 
The available crystal structures of SK with shikimic acid 
(6) in the active site show that the substrate is strongly an-
chored to the active site by a salt bridge with the guanidi-
nium group of Arg136 and by hydrogen bonding between 
the side chain of the essential Asp34 residue and the C4 hy-
droxyl group (Fig. 1B). Remarkably, shikimic acid (6) binds 
to the enzyme in an unusual and unstable conformation for a 
cyclohexene ring with two of the three hydroxyl groups (C4 
and C5) in an axial arrangement. By forcing the axial dispo-
sition of the C4 and C5 hydroxyl groups, the enzyme con-
trols the equatorial disposition of the C3 hydroxyl group and 
allows its selective phosphoryl-transfer reaction. The exqui-
site control of the axial position of the C4 hydroxyl group is 
achieved by hydrogen-bonding interactions with the essential 
Asp34 [24], the conserved Gly80 residues and a water mole-
cule, the position of which is frozen by the conserved resi-
dues Glu61, Arg58 and Gly80. The axial arrangement of the 
hydroxyl group in C5 is achieved by two water molecules 
that form a bridge between the carboxylate group and the C5 
hydroxyl group. These water molecules are always located in 
a nonpolar pocket generated by the conserved Phe49 and 
Phe57 residues located in α-helices α3 and α4, which – to-
gether with Arg117 – helps to seal the active site from the 
solvent environment. 
3.2. Essential Motions for Catalytic Turnover 
Molecular dynamics (MD) simulations performed with 
the Michaelis complex (Mt-SK/ADP/7 ternary complex) 
revealed that the strong salt-bridge interaction between the 
phosphate group in 7 and the guanidinium group of Arg117 
triggers the release of the product from the active site [25] 
(Fig. 1C). By pulling on the phosphate group in 7, Arg117 
causes the breakdown of the favorable interactions of the 
product with the active site residues, particularly the salt-
bridge interaction between the C1 carboxylate group and the 
guanidinium group of Arg136. As a consequence, a confor-
mational change in the product and a large movement of the 
SB domain takes place (up to 10 Å). During product release, 
the LID domain also undergoes large movements (up to 6 Å) 
to allow the Arg117 and Arg136 side chains to expel the 
product from the active site. 
MD simulation studies also highlighted that there are 
four key structural factors required for the catalysis [25]: (1) 
the C4/C5 diaxial conformation of shikimic acid (7); (2) a 
closed form of the LID domain to allow activation of the γ-
phosphate of ATP and stabilization of the transition state by 
the guanidinium group of the Arg117 side chain; (3) a closed 
form of the SB domain in order to bring the substrates to-
gether for the phosphoryl-transfer reaction and to isolate the 
substrate within an apolar cavity; (4) flexible LID and SB 
domains for product release. These key points have been the 
starting point for the structure-based design of mimetics of 
the natural substrate, which will be discussed below. 
3.3. Shikimate Kinase Inhibitors 
3.3.1. Substrate Mimetics 
Considering that the P-loop, which forms the binding site 
for ATP and ADP, is rather conserved in many ATP- or 
GTP-binding proteins, several mimetics of shikimic acid (6) 
964    Current Topics in Medicinal Chemistry, 2016, Vol. 16, No. 9 Concepción González-Bello 
were designed for specific binding to the SB binding site of 
this kinase [25]. Based on the aforementioned structural re-
quirements, compounds 12-13 were designed to fix the 
diaxial conformation of the C4 and C5 substituents in the 
natural substrate (Fig. 2). Both compounds proved to be re-
versible competitive inhibitors of the Mt-SK with Ki values 
of 62 and 46 µM, respectively – in both cases below the Km 
of the enzyme (544 µM). 
 
 
Fig. (2). Competitive reversible inhibitors of Mt-SK. 
 
The crystal structure of Mt-SK in complex with ADP and 
compound 12 (PDB entry 4BQS, 2.15 Å) reveals that the 
cyclohexene ring of inhibitor 12 occupies approximately the 
same site and has similar binding interactions as the natural 
substrate (Fig. 3A). Inhibitor 12 provides a tidy closed form 
of the active site and prevents the opening of the SB binding 
domain, which is required for turnover. MD simulation stud-
ies suggested that the reduction of the double bond of the 
C3-C5 ether bridge in 12 enhances the lipophilic interactions 
of this bridge with the conserved residues Arg117 and 
Pro118. This more effective reduction of the flexibility of the 
LID domain might also explain its higher inhibitory potency. 
The (3R)- (15) and (3S)-3-aminoshikimic acids (16) were 
also designed as mimetics of the natural substrate. Both com-
pounds proved to be reversible competitive inhibitors of the 
Mt-SK enzyme with Ki values of 62 and 65 µM, respec-
tively. Docking and MD simulation studies showed that both 
compounds would interact with the γ-phosphate of ATP 
through a strong electrostatic interaction and they would 
cause a dramatic reduction in the flexibility of the LID and 
the SB domains (Fig. 3B and C). 
6-Hydroxy derivatives 14 and 18 proved to be weak 
competitive reversible inhibitors of the enzyme with Ki val-
ues of 1050 and 792 µM, respectively. The MD simulation 
studies carried out with (6R)-6-hydroxyshikimic acid (18) 
showed that this compound caused significant changes in the 
water network and caused an opening of the SB domain by 
nearly 6 Å. During the simulation the ligand also undergoes 
a conformational change to the thermodynamically more 
stable conformation, i.e., with C4 and C5 hydroxyl groups in 
the pseudo-equatorial conformation. This binding conforma-
tion of 18 and the greater flexibility of the SB domain seem 
to be responsible for the lower inhibitory potency of this 
compound.  
In summary, the inhibitory properties and binding mode 
of compounds 12-18 reveal that the fixation of the diaxial 
conformation of the C4 and C5 hydroxyl groups recognized 
by the enzyme is a promising strategy for inhibition because 
it causes a dramatic reduction of the flexibility of the LID 
and shikimic acid binding domains. Moreover, the (3R)- (15) 
and (3S)-3-hydroxyshikimic acids (16) are also good scaf-
folds for the future generation of inhibitors.  
3.3.2. Inhibitors Identified by Screening 
Compounds that target the SK enzyme have also been 
discovered by screening. For example, Simithy et al. used 
LC-MS and a library of about 400 antimycobacterial com-
pounds, which were previously found by the NIH Tubercu-
losis Antimicrobial Acquisition and Coordination Facility 
(TAACF), to identify several compounds that inhibit Mt-SK 
[26]. The most active compounds were 19, 20 and 21, with 
IC50 values between 1.9 and 3.8 µM, and these contain an 
oxadiazole-amide or a 2-aminobenzothiazole moiety in their 
structure (Fig. 4). The authors used sulfonamide 22, with an 
IC50 value of 0.2 µM, previously described by Bandodkar et 
al. [27], as a positive control for the assay.  
Han et al. carried out the high-throughput screening of a 
library of about 3000 compounds and discovered two inhibi-
tors of SK from Helicobacter pylori (Hp-SK), namely com-
pounds 23 and 24, with IC50 values of 5.5 and 6.4 µM, re-
spectively (Fig. 4) [28]. Cheng et al. also identified the
 
Fig. (3). A) Crystal structure of the ternary complex Mt-SK/ADP/12 (orange, PDB entry 4BQS). B,C) Binding mode of (3R)-3-
aminoshikimic acid (15, yellow) and (3S)-3-aminoshikimic acid (16, green) obtained by MD simulation studies. Relevant side chain residues 
are shown and labeled. Polar (blue) interactions between ligands and the Mt-SK are shown. 
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Fig. (4). Selected examples of SK inhibitors identified by screening. 
 
naphthalene-2-sulfonate 25, which had an IC50 value of 4.9 
µM (Fig. 4) [29]. The authors also solved the crystal struc-
ture of E114A Hp-SK variant enzyme in complex with 25 
(PDB entry 3N2E, 2.53 Å) (Fig. 5). This structure reveals 
that the ligand prevents the closure of the active site for ca-
talysis by causing a large conformational change in the LID 
domain. Specifically, the ligand establishes two strong 
cation-π interactions, one with the conserved residue 
Arg132, which is responsible for the C1 carboxylate recogni-
tion of the substrate/product, and another with the essential 
Arg116, which is key for ATP binding and product release 
and it has been suggested that this acts as a Lewis acid dur-
ing the catalysis [25]. In addition, a strong electrostatic inter-
action between the guanidinium moiety of Arg116 and one 
of the sulfonate groups fixes the ligand between the LID and 
the SB domain. 
Moreover, the availability of several crystal structures 
of the SK enzymes, mainly from M. tuberculosis and H. 
pylori, have encouraged diverse virtual screening studies 
for the identification of potential inhibitors of these en-
zymes [30, 31].  
4. TARGETING DEHYDROQUINASE 
Dehydroquinase (3-dehydroquinate dehydratase, DHQ, 
EC 4.2.1.10) catalyzes the reversible dehydration of 3-
dehydroquinic acid (4) to form 3-dehydroshikimic acid (5) 
(Scheme 1). There are two distinct types of enzymes, known 
as type I (DHQ1, aroD gene) and type II (DHQ2, aroD/aroQ 
gene), which have different biochemical and biophysical 
properties and show no sequence similarity [32,33]. DHQ1, 
which is found in plants, fungi and bacterial species such as 
Escherichia coli, Staphylococcus aureus and Salmonella 
typhi, is exclusively biosynthetic and is a heat-labile dimer 
with a subunit of around 27 KDa. DHQ1 is a class I aldolase 
enzyme that catalyzes the syn elimination of water in 4 by a 
multi-step mechanism that involves the formation of a Schiff 
 
Fig. (5). A) Comparison of the complexes Hp-SK/ADP/7 (PDB entry 3MUF) vs Hp-SK/25 (PDB entry 3N2E). The LID and SB domains of 
both crystal structures are highlighted (yellow and pink, respectively). Note how compound 25 causes a large conformational change in the 
LID domain, thus avoiding its closure for catalysis. B) Binding interactions of compound 25 (green) in the binary complex Hp-SK/25 (yel-
low, PDB entry 3N2E). L-Tartaric acid molecules (blue) from crystallization conditions are also shown. Polar (red) interactions between 25 
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base. It has been suggested that DHQ1 may act as a viru-
lence factor in vivo as the deletion of the aroD gene affords 
satisfactory live oral vaccines, that provides monkeys with 
protection against oral challenge with live S. flexneri 2457T 
[34-37]. In contrast, DHQ2, which has both biosynthetic and 
catabolic roles and is a heat-stable dodecamer (tetramer of 
trimers) with a subunit of 16-18 KDa, catalyzes the anti 
elimination of water in 4. In contrast to DHQ1, the reaction 
mechanism of DHQ2 does not involve any covalent attach-
ment of the substrate to the enzyme through Schiff base 
formation. DHQ2 is essential in important pathogenic 
bacteria such as Mycobacterium tuberculosis (aroD gene) 
and Helicobacter pylori (aroD/aroQ gene) [17].  
The fact that two enzymes have evolved to catalyze the 
same reaction by entirely different mechanisms and stereo-
chemical courses [38] has been used for the design of com-
pounds that specifically inhibit either DHQ1 or DHQ2 en-
zymes. Of the two, particular attention has been paid to the 
inhibition of the DHQ2 enzyme as a potential target for the 
development of anti-tubercular drugs as well as for the 
treatment of infectious diseases caused by H. pylori. As a 
result, numerous potent inhibitors of this target have been 
developed. The resolution of crystal structures of several 
DHQ2/inhibitor binary complexes has undoubtedly been 
very important for this success, not only for the development 
of inhibitors of improved activity but also to gain a deeper 
understanding of its anti dehydration mechanism and the 
binding requirements of the DHQ2 enzyme.  
4.1. Mechanism and Substrate Binding 
The DHQ2 mechanism involves the loss of the more 
acidic pro-S hydrogen from C2 in 4 (Scheme 2). An arginine 
[Arg17/Arg19 in DHQ2 from H. pylori (Hp-DHQ2) and 
from M. tuberculosis (Mt-DHQ2), respectively] and a tyro-
sine (Tyr22/Tyr24 in Hp-DHQ2 and Mt-DHQ2, respec-
tively) have been identified by chemical modification and 
site-directed mutagenesis studies as being essential for en-
zyme activity [39,40]. Both residues are on the flexible loop 
that closes over the active site upon substrate binding. In the 
absence of any crystal structure and based on kinetic isotope 
effects and pH profile studies carried out on Mt-DHQ2 and 
Aspergillus nidulans DHQ2 (An-DHQ2), Harris et al. [41] 
suggested that the elimination proceeds by a stepwise E1CB 
mechanism via enolate intermediate 26 (Scheme 2). Subse-
quent resolution of the DHQ2 from Streptomyces coelicolor 
(Sc-DHQ2) with an inhibitor in the active site (PDB entry 
1GU1, 1.8 Å) by Roszak et al. [42] allowed a detailed de-
scription of the active site and provided a good knowledge of 
the specific functions of individual amino acid residues. The 
substrate is strongly bound to the active site by a series of 
hydrogen bonding interactions through the carboxylate group 
and the three hydroxyl groups. In particular, the carboxylate 
binding pocket is a key part in the recognition and this gives 
rise to four strong hydrogen bonding interactions involving 
the main chain amide NH groups of Ile102 and Ser103, the 
side chain OH group of Ser103 and the side chain amide of 
the conserved Asn75 (in Mt-DHQ2). The latter residue also 
acts by correctly positioning the C1 hydroxyl group to accept 
a proton from the conserved His101. In addition, the C5 hy-
droxyl group interacts by hydrogen bonding with the con-
served His81 and Arg112 residues and Asp88* forms the 
major interaction with the C4 hydroxyl group. The reported 
crystal structure reveals two key facts: (a) the absence of any 
suitable residue that could stabilize an enolate intermediate; 
(b) the presence of a conserved water molecule (henceforth 
WAT1) in close proximity to the position that would be oc-
cupied by the enolate intermediate 26. On the basis of these 
structural considerations, the authors suggested that the reac-
tion is initiated by the essential tyrosine, which removes the 
pro-S hydrogen from C2 of 4 to afford an enol intermediate. 
The final step is the acid-catalyzed elimination of the C1 
hydroxyl group – a reaction mediated by the conserved his-
tidine His102/His101 (in Hp-DHQ2 and Mt-DHQ2, respec-
tively) acting as a proton donor. However, the suggested 
formation of an enol rather than an enolate intermediate did 
not explain the observed solvent isotope effects and proton 
inventory of Mt-DHQ2, in which there is a single proton 
Scheme 2. Proposed mechanism for the reaction catalyzed by Mt-DHQ2. Relevant residues are indicated and labeled. Hydrogen bonds are 
shown as dashed lines. Note how Asp88* from a neighboring enzyme subunit is responsible for the generation of the catalytic form of the 
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contributing to this effect [41]. On the basis of results from 
quantum mechanical (QM) calculations using different Ham-
iltonians on Sc-DHQ2, Blomberg et al. [43] subsequently 
suggested again the formation of enolate intermediate 26 
because of its significantly lower energy compared to that of 
the enol intermediate. 
More recently, hybrid QM/MM (quantum mechan-
ics/molecular mechanics) calculations and biochemical stud-
ies have provided a good understanding of the catalytic 
mechanism in atomic detail and provided details of the re-
quired motions for the catalytic turnover [44]. Remarkably, 
these studies clarified how the catalytic form of the essential 
tyrosine (tyrosinate) is formed and the role of the essential 
arginine in the enzymatic catalysis. These studies showed 
that an aspartate from the neighboring enzyme subunit 
(Asp89*/Asp88* in Hp-DHQ2 and Mt-DHQ2, respectively; 
residues from this subunit are marked with an asterisk) is the 
residue responsible for the deprotonation of the essential 
tyrosine to afford the catalytic tyrosinate, which triggers the 
enzymatic process (Fig. 6). The essential nature of this resi-
due was corroborated by site-directed mutagenesis studies. 
For Hp-DHQ2, this reaction takes place with the assistance 
of a water molecule (Fig. 6B), while for Mt-DHQ2 the tyro-
sine is directly deprotonated by the aspartate residue (Fig. 
6A). These results are consistent with the solvent isotope 
effects and proton inventory [44], which shows that there are 
at least two protons involved in the reaction, one associated 
with the elimination step and another/others involved in ty-
rosine deprotonation. These studies also show that the gua-
nidinium group of Arg17/Arg19 must be close to the essen-
tial tyrosine side chain for catalysis. In this arrangement, the 
arginine controls the appropriate orientation of the tyrosine, 
which is roughly perpendicular to the cyclohexane ring of 
the natural substrate, through a cation-π interaction and con-
tributes to decreasing the pKa of the phenol group. The ty-
rosinate removes the axial hydrogen from C2 of 4 to give an 
enolate intermediate 32 (Fig. 6C), which is stabilized by the 
positively charged side chain of the essential Arg17/Arg19 
and by a hydrogen bond between the neutral aspartate 
Asp89*/Asp88* and the conserved water molecule WAT1.
The presence of WAT1 in many crystal structures and its 
role in the enzymatic mechanism have been widely dis-
cussed. WAT1 interacts through hydrogen bonding with a 
conserved asparagine (Asn10/Asn12 in Hp-DHQ2 and Mt-
DHQ2, respectively), the carbonyl group of a conserved 
proline (Pro9/Pro11 in Hp-DHQ2 and Mt-DHQ2, respec-
tively) and the main-chain amide of a glycine or an alanine 
(Ala79/Gly78 in Hp-DHQ2 and Mt-DHQ2, respectively). 
Initially, it was proposed that WAT1 would be involved in 
the enzymatic mechanism [42]. However, QM/MM studies 
suggest that WAT1 would be mainly involved in the stabili-
zation of the substrate and enol intermediate 32 [44]. 
4.2. Reversible Competitive Inhibitors  
Based on the reaction mechanism, a large number of 
competitive reversible inhibitors have been developed 
[45,46]. In general, these compounds are either analogs of 
the natural substrate or mimetics of the enolate intermediate 
26. The structural changes (binding, motion, conformation) 
caused by these compounds, which are responsible for their 
inhibition activity, are discussed below. 
4.2.1. Substrate Analogs  
Reasoning that the reaction catalyzed by DHQ2 involves 
the abstraction of the axial hydrogen from C2 of 4, a good 
strategy to inhibit the enzyme proved to be the substitution 
of the axial hydrogen by a group that is able to interact with 
the base responsible for this process, i.e., the tyrosine. Nev-
ertheless, we have shown that substrate analogs equatorially 
substituted at C2 by benzyl groups are also good reversible 
competitive inhibitors of the enzyme, since the methylene 
group of the benzyl group allows the aromatic ring of the 
inhibitor to be located close to the tyrosine ring. Indeed, the 
substitution of either the pro-S or pro-R hydrogen at C2 of 4 
by a functionalized benzyl group, compounds 27 and 28, 
respectively, provides good reversible competitive inhibitors 
of the DHQ2 enzyme (Fig. 7) [47,48]. 
The resolution of the crystal structures of the binary 
complexes between Mt-DHQ2 and Hp-DHQ2 and one of the 
Fig. (6). Detail view of the DHQ2 Michaelis complexes and enolate intermediate 26 geometries obtained by QM/MM studies: A) Mt-DHQ2 
Michaelis complex. B) Hp-DHQ2 Michaelis complex. C) Hp-DHQ2 enolate intermediate 26 geometry. Note how Asp88*/Asp89* from a 
neighboring enzyme subunit is responsible for the generation of the catalytic form of the essential tyrosine (tyrosinate). For Hp-DHQ2, this 
reaction takes place with the assistance of a water molecule. Relevant residues and water molecules are indicated and labeled. Hydrogen 
bonds and key distances are shown. 
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most potent inhibitors of the 2R-substituted derivatives 28, 
i.e., 4-methoxybenzyl derivative 28b, which has Ki values of 
26 nM and 170 nM, respectively, has been very important in 
understanding the role of the aromatic moiety for inhibition 
(Fig. 8A and C) [49]. These crystal structures reveal that 
these compounds inhibit DHQ2 because their aromatic func-
tional groups block the catalytic arrangement of the tyrosine 
and the arginine, i.e., it avoids the cation-π interaction be-
tween the guanidinium group of Arg17/Arg19 and the phe-
nol group of the tyrosine side chain. In particular, the aro-
matic moiety of 28b interacts with the catalytic tyrosine by 
π-stacking and, more importantly, expels the arginine side-
chain from the active site. 
 
27/28 M. tuberculosisa H. pylorib S. coelicolorc 
27a 90 1180 1050 
27b 90 970 150 
27c 100 1420 340 
27d 74 970 7 
27e 56 900 38 
28a 100 1400 1550 
28b 26 170 34 
28c 89 250 22 
28d 47 2600 242 
28e 28 160 4 
apH 7.0, 25 ºC, 50 mM Tris.HOAc (Km = 15 µM). bpH 7.0, 25 ºC, 50 mM Tris.HCl (Km 
= 448 µM). cpH 7.0, 25 ºC, 50 mM Tris.HCl (Km = 250 µM). 
Fig. (7). 2-Benzyl-3-dehydroquinic acids 27-28, competitive rever-
sible inhibitors of DHQ2 enzyme. Ki (nM) values of compounds 
27-28 against DHQ2 from different sources are shown. 
Moreover, MD simulations suggest that the benzyl 
groups of ligands 28 inactivate the enzyme by causing a sig-
nificant conformational change of the substrate-covering 
loop and a dramatic reduction of its flexibility, which is es-
sential for the function of the enzyme [49]. In fact, this ap-
proach allowed the resolution of the M. tuberculosis loop 
containing residues 20-25 for the first time (Fig. 8A, PDB 
entry 2XB8, [49]). It is important to highlight that the 2R-
substituted derivatives 28 still contain the axial hydrogen 
that could be removed by the essential tyrosine, the residue 
that triggers the dehydration reaction. 
For the Hp-DHQ2 enzyme and regardless of the type of 
substituent of the aromatic ring, the binding mode of the 
2S- 27 and 2R-2-benzyl derivatives 28 are quite similar, 
which could explain the similar inhibition constants ob-
tained (Fig. 8C and D) [49,50]. In all cases, the essential 
Arg17 is expelled from the active site and faces away from 
the essential Tyr22. In contrast, for the Mt-DHQ2 enzyme 
there are significant differences in the binding mode of 
these compounds depending on the type of substituent on 
the aromatic ring. Thus, all of the inhibitors cause a dra-
matic reduction of the loop flexibility, albeit by a different 
mechanism (Fig. 8C and D) [49,50]. For instance, the per-
fluorobenzyl derivative 27d causes the complete closure of 
the active site through the formation of a strong π -π stack-
ing interaction with the aromatic ring of Tyr24 and a favor-
able electrostatic interaction with the guanidinium group of 
Arg19. In contrast, the 4-methoxybenzyl derivative 27b 
favors a more open conformation of the loop, with Arg19 
facing out of the active site. 
4.2.2. Enolate Intermediate Mimetics 
Bearing in mind the fact that the elimination mechanism 
of the DHQ2 enzymes proceeds via enol intermediate 26, 
which is characterized by ring-flattening between the C2-C3 
bond, Frederickson et al. [51] designed the first mimetic of 
the enolate intermediate, 2,3-dehydroquinic acid (29), which 
proved to be a reversible competitive inhibitor of Mt-DHQ2 
and Sc-DHQ2 with Ki values of 200 µM and 30 µM, respec-
tively (Fig. 9). These authors subsequently replaced hydro-
gen H3 of 29 by a fluorine atom, compound 30, in order to 
mimic the high electron density generated at C3 during the 
course of the reaction [52,53]. This substitution provides a 
more potent analog of 29, with Ki values of 10 µM and 15 
µM, respectively.  
 
Fig. (8). Conformational changes of the substrate-covering loop observed in crystal structures of DHQ2 in complex with 2-benzyl-3-
dehydroquinic acids 27d and 28b. A) Mt-DHQ2/28b (PDB entry 2XB8, 2.4 Å). B) Mt-DHQ2/27d (PDB entry 4B6P, 2.3 Å). C) Hp-
DHQ2/28b (PDB entry 2XB9, 2.75 Å). D) Hp-DHQ2/27d (PDB entry 4B6S, 1.9 Å). The substrate-covering loop (yellow, light orange) 
and relevant side chain residues are shown and labeled.
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Fig. (9). Mimetics of the enolate intermediate 29 that are competitive reversible inhibitors of the DHQ2 enzyme. 
 
The important observation that compounds with a double 
bond between C2-C3 bind in the manner predicted for transi-
tion state mimetics, as revealed by the crystal structure of Sc-
DHQ2 with 29 bound in the active site (PDB entry 1GU1, 
1.8 Å, [42]), inspired the structure-based design of new 
compounds with improved inhibition properties. Specifi-
cally, the 3-substituted cyclohexene derivatives 31-36, the 
tetrahydrobenzothiophene derivatives 37, the O-alkyl deriva-
tives 38, and the 2,3-disubstituted compounds 39 were re-
ported (Fig. 9) [54-71]. A summary of the inhibition con-
stants of these compounds against Mt-DHQ2 and Hp-DHQ2 
are shown in Tables 1 and 2. 
The idea of adding substituents at the C3 position arose 
from the X-ray crystal structure of the Sc-DHQ2/29 binary 
complex (PDB entry 1GU1) reported by Roszak et al. [42]. 
In the active site of this structure it was observed that, in 
addition to 29, a molecule each of glycerol and tartrate, 
originating from the enzyme storage buffer, were present at 
distances of 3.7 Å and 4.6 Å from the inhibitor 29, respec-
tively. This suggested the existence of additional positions in 
the vicinity of 29 that could be used to enhance the binding 
affinity of the enzyme by the inhibitor. In particular, the in-
corporation at the C3 position of 29 of groups that could 
interact with the residue triggers the formation of the enolate 
intermediate 26, the tyrosine. This possibility was first stud-
ied by incorporation of aromatic rings at the C3 position in 
29 in order to establish π-stacking interactions with the tyro-
sine ring. These studies led to the discovery of the most po-
tent inhibitor at that time against any DHQ2, the 3-
nitrophenyl derivative 32.7, with a Ki value of 54 nM 
(against Mt-DHQ2) [54,55]. At that time a crystal structure 
of Mt-DHQ2 with a full description of the substrate-covering 
loop in which the essential tyrosine and arginine are located 
was not available and NMR studies [Saturation Transfer Dif-
ference (STD) and 1D and 2D-TR-NOESY experiments) 
were performed to determine its binding mode [56]. These 
studies showed that only one of the conformations existing 
in solution for this inhibitor is selected when bound to the 
active site of Mt-DHQ2. In the bound state, the 3-nitrophenyl 
unit of the potent inhibitor 32.7 is frozen in one orientation 
relative to the cyclohexene ring, with the nitro group orien-
tated towards double bond side. In this arrangement, the ni-
tro group establishes a strong π-stacking interaction with the 
phenol group of the essential tyrosine. These initial results 
were very important in highlighting that the incorporation of 
aromatic rings at C3 improves dramatically the inhibitory 
potency and resulted in numerous subsequent structure-based 
studies to improve this activity further. 
Another result of these investigations was the resolution 
of several crystal structures of diverse enzyme-inhibitor 
complexes that have been instrumental in gaining a deep 
understanding of the role of the substituents in the cyclohex-
ene core of 29. Among them, it is worth noting two crystal 
structures of Mt-DHQ2 solved at 1.5 Å. The first one is the 
structure with a 2,3-disubstituted compound 39 (39.8, Ar = 
benzo[b]thiophen-2-yl; 2R = methylthien-2-yl) (PDB entry 
2Y77) bound in the active site (Fig. 10A) [66]. This struc-
ture revealed that the 2,3-disubstituted compounds might 
inhibit the enzyme by a double effect. Thus, as for 2-benzyl 
derivative 28b in PDB entry 2XB8, the aromatic moiety at 
C3 in the 2,3-disubstituted compounds blocks the entry of 
the essential arginine side chain into the active site. In addi-
tion, the benzyl substituent at C2 prevents the hydrogen-
bonding interaction of Arg108 with the essential Tyr24 of 
the substrate-covering loop, i.e., the residue that initiates 
catalysis (Fig. 10A). These results suggest that compounds 
that are able to block the alignment between Tyr24 and 
Arg108 would also be good competitive inhibitors of DHQ2 
enzymes. 
The second crystal structure that is worth highlighting is 
the one in complex with an O-alkyl derivative 38 (38.2, Ar 
= 5-methylbenzo[b]thiophen-2-yl) (PDB entry 2Y71) 
bound in the active site [66]. This compound has Ki val-
ues of 42 nM [66] and 130 nM [63] against Mt-DHQ2 and 
Hp-DHQ2, respectively. As in PDB entry 2Y77, the essen-
tial arginine is out of the active site. More importantly, this 
structure reveals that the oxygen atom of the methyleneoxy 
spacer of the inhibitor is located 3.1 Å away from WAT1 
(Fig. 10B). This suggests that an important contribution to 
the high potency of inhibitors of these types is the interac-
tion between the oxygen atom of the methyleneoxy spacer 
and WAT1 and this aspect should therefore be considered in 
the structure-based design of inhibitors. Indeed, the re-
placement of the oxygen atom of the methyleneoxy spacer 
of 38 by a carbon atom (ethylene spacer, compounds 36, 
[68]) leads to a decrease in the inhibition potency by up to 
20-fold. The inhibition data, together with the results of MD 
simulation studies, show that, in general, effects of the ge-
ometry and size of the alkyl spacer are more pronounced in 
the inhibition efficiency of the Hp-DHQ2 enzyme. For both 
enzymes, compounds with a flexible spacer proved to be 
more potent than compounds with a more rigid one because 
it provides the necessary conformational flexibility for the 
aryl moiety to be accommodated in the active site in an ex-
tended conformation. Docking studies suggest that com-
pounds with a three-carbon spacer fit more efficiently into 
the active site than the corresponding two-carbon spacer 
analogs because they locate the aromatic ring closer to the 
aliphatic residues of the enzyme active site. For instance, 
replacement of the ethylene spacer in 36.1 by a propylene 
one, compound 36.4, leads to a decrease in the inhibition 
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Table 1. Selected examples of reversible competitive inhibitors of DHQ2 enzymes. Ki (µM) values of compounds 29-37 against Mt-
DHQ2 and Hp-DHQ2 are shown. 
Compd G Mt-DHQ2 Hp-DHQ2 Ref Compd G Mt-DHQ2 Hp-DHQ2 Ref 
29 H 200 370 [51] 32.20 
S  
13.2 -- [57] 
30 F 10 -- [52] 32.21 O
 
0.83 4.85 [55,57] 
31 CO2H 0.94 -- [58] 32.22 S
 
0.59 1.8 [55,57] 
32.1 
 
1.5 7.4 [55,57] 32.23 HN
N N  
2.5 63 [61] 
32.2 
F  




3.75 -- [57] 
32.3 
F3C  
17 8.4 [55,57] 32.25 
O
 




1.5 9.4 [55,57] 32.26 
S
 




2.13 139 [55,57] 32.27 
S
Br  




95 128 [55,57] 32.28 
S
CN  




0.054 38.4 [55,57] 32.29 
S
NO2  




150 150 [55,57] 32.30 
S
NO2  




2.4 20.5 [55,57] 32.31 
O
 




45 56 [55,57] 32.32 
S
 
0.38 1.2 [59] 
32.11 
O2N  




>100 24 [59] 
32.12 
NO2  
1.9 141 [57] 32.34 
O
 
11 2.9 [59] 
32.13 
 




0.91 -- [60] 
32.14 
O  






8.7 -- [60] 
32.15 
S  







49 -- [60] 
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(Table 1) contd…. 












0.85 8.1 [57] 34.1 
 





>300 -- [57] 34.2 F
 





1.95 -- [57] 34.3 
O2N
 




0.11 0.10 [64] 36.1 
2  
0.44 0.79 [68] 
34.5 
N  
2.19 0.71 [64] 36.2 
2  
0.27 1.15 [68] 
34.6 
N  




0.25 2.46 [68] 
34.7 
S  
0.19 0.32 [64] 36.4 
3  








0.07 0.29 [68] 
35.1 
 












0.12 -- [60] 37.4 
 




















20 -- [60] 37.8 isopropyl 0.19 3.4 [65] 
35.9 HO2C  
105 -- [60] 37.9 
 
0.11 1.08 [65] 
35.10 HO  17 -- [60] 37.10  
0.09 0.60 [65] 
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Table 2. Selected examples of reversible competitive inhibitors of DHQ2 enzymes. Ki (nM) values of compounds 38-39 against Mt-
DHQ2 and Hp-DHQ2 are shown. 
Compd Ar 
2
R Mt-DHQ2 Hp-DHQ2 Ref 
38.1 
S  
H 28  132 [63,66] 
38.2 
S  
H 42.5 130 [63,66] 
38.3 
SCl  
H 35 205 [66] 
38.4 
S  
H 31 166 [63,66] 
38.5 
 
H 35 310 [66] 
38.6 
S  
H 235 920 [63,66] 
39.1 
S  S  
40 97 [66] 
39.2 
S  S  
188 50 [66] 
39.3 
SCl  SCl  
1100  6700  [66] 
39.4 
S  S  
440  140 [66] 
39.5 
  
6000  260  [66] 
39.6 
S  S  
5100  14600  [66] 
39.7 
S  
allyl 1240 1100 [66] 
39.8 
S  S  
250 280 [66] 
39.9 
S  S  
870 279 [66] 
39.10 
S  S  
59  100 [66] 
 
Taking into account the important stabilizing contribu-
tion that the interaction between WAT1 and either enolate 
mimetics like compound 38, the natural substrate or the 
enolate intermediate 32 seem to have in their binding with 
the DHQ2 enzyme, the WAT1 binding pocket was also ex-
plored in the structure-based design of inhibitors of these 
enzymes [70]. This aspect was explored with compounds 40-
43 (Fig. 11). 
The crystal structures of Mt-DHQ2 in complex with 
compounds 40 (PDB entry 4CIV, 2.9 Å) and 41 (PDB entry 
4CIW, 2.2 Å) show that, in the absence of the benzyl group, 
the hydroxyl group of the C3 side chain of these compounds 
does not interact with WAT1 and does not occupy the 
WAT1 binding pocket. However, in the presence of the ben-
zyl group in the C3 side chain, important differences in the 
binding mode interactions with WAT1 and the WAT1 bind-
ing pocket are observed (Fig. 12). The crystal structures of 
Mt-DHQ2/42a (PDB entry 4CIX, 2.9 Å) and Mt-DHQ2/43a 
(PDB entry 4CIY, 2.1 Å) binary complexes, along with the 
inhibition data and results of MD simulation studies with the 
corresponding chlorides 42b and 43b, reveals that analogs 
with the R configuration on the C3 side chain, which also 
bind to the active site with an extended conformation of this 
chain, are more potent because, in this arrangement, they 
promote interactions with WAT1 and the residues located 
within this pocket. More importantly, the binding affinity is 
reduced if the ligands occupy the WAT1 binding pocket. 
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Fig. (10). A) Overlapping of the crystal structure of Mt-DHQ2 (gray) with a 2,3-disubstituted compound (39.8, pink) in the active site (PDB 
entry 2Y77, 1.5 Å) with the substrate-covering loop (closed form) of Mt-DHQ2/28b binary complex (PDB entry 2XB8). B) Interactions 
of the O-alkyl derivative 38 (38.2, 1R = 5-methylbenzo[b]thiophen-2-yl) with Mt-DHQ2 (PDB entry 2Y71, 1.5 Å). Polar interactions be-
tween the ligand, WAT1 and Mt-DHQ2 are shown as blue dashed lines. WAT1 and relevant residues are shown and labeled. 
Fig. (11). Designed mimetics of the enolate intermediate 26 to 
explore the WAT1 binding pocket of the DHQ2 enzymes. Ki (µM) 
values for compounds 40-43 against Hp- and Mt-DHQ2 enzymes 
are shown. 
 
The binding requirements of the DHQ2 active site, par-
ticularly regarding the carboxylate binding pocket, which is 
a key part in the enzyme recognition, has been a major chal-
lenge in order to achieve optimal in vitro antibacterial activ-
ity, especially in the anti-tubercular case. However, an ester 
prodrug approach proved to improve permeability of the 
mycobacterial cell and therefore the antibacterial activity 
[66]. The stability of the ester proved to be crucial to achieve 
improved in vitro activities. In general, the activity dramati-
cally increases with the stability of the ester. Propyl esters 
were the most potent of the series, with MIC values of 5 
µg/mL. These initial results have been very important to 
prove that the DHQ2 enzyme is a good target for the devel-
opment of novel antibiotics. However, further improvement 
of the prodrug approach is required to achieve the nanomolar 
activity obtained with the isolated enzyme. 
In this context, and in the search for drug-like aromatic 
inhibitors of Mt-DHQ2, several 3-nitrobenzylgallate-based 
analogs 44-46 with inhibitory activities in the micromolar 
range have recently been described [71,72] (Fig. 13). 
2.3. QSAR Studies  
The large number of inhibitors described and the avail-
able structural data have allowed the development of QSAR 
models for the Hp-DHQ2 and Mt-DHQ2 enzymes and these 
aid in rationalizing the determinants of binding affinity and 
in understanding the differences between the two enzymes. 
Thus, comparative binding energy (COMBINE) analysis 
allowed quantification of the contribution of each active site 
residue to inhibition of the two enzymes [73]. 
For Hp-DHQ2, these QSAR studies identified the van der 
Waals interactions with Asn10, Met13, Leu14, Tyr22, 
Leu103, His102 and Gly78, and Gln63* and Ala90* of a 
symmetry-related neighboring subunit, as well as the electro-
static and hydrogen bonding interactions with the WAT1 wa-
ter molecule, as those that contribute most significantly to 
explaining the differences in inhibitory potency [74]. For Mt-
DHQ2, the QSAR model is dominated by van der Waals in-
teractions with active site residues Tyr24, Leu13, Leu16, 
Ile102, Gly77, Asn75 and His101, and with Ala91* and 
Glu92* of the neighboring subunit, as well as by interactions 
with the WAT1 water molecule and the crystallographic wa-
ter molecule close to Arg108 and Tyr24. In general, the key 
binding interactions of the inhibitors with the enzymes can be 
organized into five key pockets: (1) the substrate-covering 
loop (Tyr); (2) the interface between chains; (3) the WAT1 
binding pocket; (4) the C2 binding pocket; and (5) the C1 
binding pocket. For both enzymes, it is worth noting the cru-
cial contribution of the ligand interactions with the WAT1 
water molecule and with the interface pocket close to the ac-
tive site, which are responsible for significant differences 
between the two enzymes. In particular, for Hp-DHQ2 these 
studies suggested that enzyme inhibition might be enhanced 
by promoting interactions between the ligand and residues 
located at the ‘bottom’ of the interface, and avoiding contacts 
with residues located at the ‘upper part’ of the interface. For 
Mt-DHQ2, improving the van der Waals interactions with 
residues located at the entrance to the interface might provide 
more potent inhibitors. For both enzymes, extending the con-
tacts with the essential aspartate would be unfavorable. 
CONCLUSION 
Despite the recognized need for new antibiotics, only two 
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Fig. (12). Binding interactions of inhibitors 42 and 43 with WAT1 and the WAT1 binding pocket of Mt-DHQ2 obtained by X-ray crystallog-
raphy and MD simulation studies. A) Binary complex Mt-DHQ2/43a (PDB entry 4CIY, 2.1 Å). B) Binary complex Mt-DHQ2/42a (PDB 
entry 4CIX, 2.9 Å). C,D) Comparison of the binding mode of S-chloride 42b (C) and R-chloride 43b after minimization and prior simulation 
(gray) and after 10 ns of dynamic simulation (light orange and yellow, respectively). Relevant hydrogen-bonding (red), halogen-bonding 
(blue) and CH….Cl interactions (black) are shown. 
 
decades. Besides this alarming trend, research into the 
discovery of new drugs by large pharmaceutical companies 
has dwindled. Hence, there is great interest in the 
development of alternative therapies, in particular the 
identification of new therapeutic targets and the discovery of 
compounds that target them. In fact, many antibiotics that 
are highly successful in human clinical use inhibit only a few 
essential processes for bacterial survival. In this context, the 
enzymes involved in the biosynthesis of aromatic amino ac-
ids are recognized as attractive targets for antibiotic drug 
discovery because they are essential in many pathogenic 
bacteria but are absent in mammals. It is therefore not sur-
prising that, in recent years, the enzymes involved in this 
pathway have attracted a great deal of attention, particularly 
shikimate kinase and type II dehydroquinase, for the discov-
ery of new anti-tubercular drugs and novel treatments for 
infections caused by Helicobacter pylori bacterium.  
Fig. (13). Selected examples of drug-like aromatic inhibitors of Mt-
DHQ2.
Several selective inhibitors of these enzymes have been 
developed based on the mechanism of action of these en-
zymes and the available crystal structures. Most of the de-
veloped inhibitors are either analogs of the natural substrate 
recognized by the enzyme or mimetics of the reaction inter-
mediate catalyzed by them. Some examples of inhibitors 
identified by screening have also been described. This suc-
cess has benefitted from very important biochemical and 
structural studies and from the computational calculations 
performed with the solved crystal structures. These studies 
have provided an in-depth knowledge of the reaction mecha-
nism and the determinants of binding affinity for these in-
hibitors. The examples summarized in this review show that, 
in both cases, those compounds that are able to reduce the 
flexibility of the substrate-covering loop, which is essential 
for catalytic turnover, is a good strategy for inhibition. For 
the DHQ2 enzyme, those compounds that are able to disturb 
the catalytic arrangement of the essential tyrosine and argin-
ine are very potent inhibitors. Thus, potent inhibitors are 
afforded by avoiding the entrance into the active site of the 
arginine side chain or blocking its cation-π interaction with 
the tyrosine phenol group. Another efficient strategy is either 
preventing the hydrogen-bonding interaction of the tyrosine 
with the conserved Arg108 (in Mt-DHQ2) of the active site 
or establishing a π-stacking interaction with the tyrosine side 
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inhibitors with the interface between chains is responsible 
for the different inhibition potency against the two DHQ2 
enzymes and this is crucial to achieve high affinity ligands. 
The most challenging issue in targeting the enzymes of 
this pathway is the high polarity of the inhibitors, mainly due 
to the carboxylate recognition that is required for good bind-
ing affinity. This makes it difficult to achieve good delivery 
of the inhibitors inside the cells. However, the fact that an 
ester prodrug approach proved to improve permeability into 
the mycobacterial cell, which is a Gram-positive bacterium 
but with characteristics of the Gram-negative ones due to the 
peptidoglycan layer in its cell wall, to provide optimal MIC 
values is highly encouraging. This finding has opened the 
door for the future development of new and more effective 
ways to deliver these inhibitors inside the cell. More impor-
tantly, it has proved that these enzymes are good targets for 
the development of inhibitors that can be used as drugs. 
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